Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229573 | 0.84 | CCR1 (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29598182 | 0.83 | NOS3 (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL17560548 | 0.82 | NOS1 (0.47) | SIGMAR1NOS1NPFFR1NPFFR2NPC1 | |
| SCHEMBL15142870 | 0.81 | NPFFR1 (0.51) | NOS3NOS1NOS2NPFFR1NPFFR2 | |
| SCHEMBL7043632 | 0.81 | NPFFR1 (0.47) | NPFFR1NPFFR2NPC1MAPTMAPK1 | |
| SCHEMBL7231945 | 0.79 | BACE1 (0.37) | NPFFR1NPFFR2LMNAHTTRAB9A | |
| SCHEMBL30897411 | 0.79 | CRHR1 (0.44) | CRHR1NPFFR1NPFFR2NPC1MAPT | |
| SCHEMBL17560319 | 0.79 | RAB9A (0.48) | NPC1LMNAMAPTMAPK1STAT1 | |
| SCHEMBL17560540 | 0.78 | MAPT (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL281590 | 0.76 | RAB9A (0.59) | NPC1LMNAMAPTMAPK1STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | PIERRE FABRE MEDICAMENT (FR) | 2019-06-18 | — | — | US | disclosed |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | PIERRE FABRE MEDICAMENT (FR) | 2019-06-18 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| EP-3189061-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034637-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034637-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | JAK2, JAK3, JAK1 | HTR3E 3283/4885HTR3B 3600/4885HTR3A 3215/4885 |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | JAK2, JAK3, JAK1 | HTR3E 3283/4885HTR3B 3600/4885HTR3A 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.